We aim to identify biomarkers associated with genetic susceptibility to cancer, carcinogenesis, disease progression and response to treatment, with the objective of developing and introducing new tests and treatments for cancer. Our specialist areas of activity are bone oncology, vascular targeting and genetic instability.

• Excellent access to a wide range of tumour types through the established North Trent Cancer Network.
• Excellent clinical research infrastructure centred at Weston Park Hospital, with experienced data managers and research nurses.
• Phase I capability recently enhanced through the appointment of Dr Sarah Danson.
• Internationally competitive bone oncology and vascular biology groups.